drugset

drugset / Trial / NCT05305365

Study Assessing QBS72S For Treating Brain Metastases

NCT05305365 ↗

Phase 2 Active not recruiting 21 enrolled Stanford University Quadriga Biosciences, Inc. · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic cancer with CNS involvement

Timeline

Start: 2022-08-16
Primary completion: 2025-06-20
Completion: 2027-12

Publications

Taiwo R, Harary PM, Trinh TTH, Granucci M, Bertrand S, Carlson-Clarke B, Chernikova SB, Therkelsen K, Arora M, Melisko ME, Iv M, Vogel H, Han S, Xie C, Brain S, Lee V, Bharani KL, Nagpal S, Hayden Gephart M. Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases. BMC Cancer. 2025 Aug 15;25(1):1316. doi: 10.1186/s12885-025-14282-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	QBS10072S	Unknown	18 mg/m2	Intravenous

Indications